Full-Time

Director – Design Quality Assurance

Calyxo

Calyxo

201-500 employees

Develops and markets kidney stone devices

Compensation Overview

$200k - $230k/yr

+ Stock Options + Variable Incentive Plan

Pleasanton, CA, USA

In Person

Must be willing to travel 10-15% domestically and internationally.

Category
QA & Testing (1)
Required Skills
Risk Management
Data Analysis
Requirements
  • Education: Bachelor of Science in Engineering or Life Science discipline.
  • Minimum 15 years experience in Quality Engineering/Assurance in the medical device industry including 5 years in a managerial role.
  • Work location: Pleasanton, CA.
  • Travel: Ability to travel 10 - 15% Domestic and International to suppliers and contract manufacturing sites.
  • Full-time employment.
  • Strong knowledge of FDA requirements for design control of medical devices and 21 CFR 820; ISO 13485 and 14971, 62366; IEC 60601-1, IEC 62304 and related regulations.
  • In depth knowledge of Risk Management, Biocompatibility, and Sterilization.
  • Strong written, oral, interpersonal skills, analytical skills, problem-solving techniques, and statistical application experience.
  • Proactive leader who can determine deficiencies, communicate them effectively through the organization, and follow through to resolution.
  • Excellent level of organizational skills and ability to direct and oversee multiple projects/initiatives at the same time with a high level of attention to detail.
  • Strategic yet hands-on when needed; high degree of energy and drive; and the ability to continually seek to make improvements to the function, process and people being led.
  • Excellent leadership and managerial skills with the ability to be flexible, adaptable and to work under pressure.
  • Experience with FDA Class II sterile devices.
  • Compliance with relevant county, state, and Federal rules regarding vaccinations.
Responsibilities
  • Lead the Design Quality Assurance team and ensure compliance with applicable domestic and international regulatory standards (e.g., FDA, CE marking, etc).
  • Oversee Design Quality Assurance and Engineering activities including the development, documentation, implementation and maintenance of quality system requirements and procedures related to design, development, and pre-production manufacturing activities.
  • Partner with R&D to ensure product development activities and deliverables are compliant with internal procedures, external standards and regulations, and industry best practices.
  • Provide Quality Engineering leadership, resources, and support to ensure the on-time development and commercialization of quality products.
  • Oversee and direct Quality staff to ensure ample coverage and support for the R&D team to support new product development (NPD)and sustaining product engineering.
  • Responsible for overseeing, planning, leading and driving activities such as Risk Management, Biocompatibility, Shelf-Life Studies, Test Method Validation, Reliability Engineering, and Statistical Analysis in support of new product development, product changes, and sustaining product engineering.
  • Ensure robust design control, software development and risk management practices are followed, driving improvements in test methods, validation, and verification processes.
  • Champion quality engineering principles and foster a company-wide continuous improvement mindset, promoting shared responsibility for quality.
  • Responsible for talent management including recruiting, engaging, training, and developing quality staff to ensure the necessary skill sets and competencies to meet business needs.
  • Establish, foster, and maintain successful cross-functional relations with internal departments/functions such as Operations/Manufacturing, R&D/Engineering, Regulatory and Clinical Affairs.
  • Interface with all departments to provide leadership on the use of Quality Assurance and Engineering methodologies, tools and regulatory compliance requirements
  • Serve as Subject Matter Expert for areas of responsibility during internal and external audits
  • Work in accordance with the quality system procedures related to work activities.
  • Develop, establish, monitor, and report on functional quality objectives, metrics, and goals.
  • Manage department expenses in-line with approved department budgets.
  • Supporting department specific initiatives and projects as assigned.
  • Contribute to our culture of being collaborative, respectful, transparent, ethical, efficient, high-achieving, and fun!

Calyxo, Inc. develops medical devices for kidney stone treatment. Its products are designed for use by urologists in hospitals and clinics to treat kidney stones more effectively, prioritizing patient safety and efficient procedures. The company works closely with leading U.S. urologists to translate clinical needs into devices, focusing on making treatments safer and easier for clinicians. Unlike some competitors, Calyxo emphasizes clinician collaboration and proven clinical relevance in its device development, backed by leadership with startup and product-launch experience. The goal is to improve patient care by delivering advanced devices that help urologists achieve better clinical outcomes and expand the devices’ reach through commercialization to healthcare providers.

Company Size

201-500

Company Stage

Series F

Total Funding

$137.2M

Headquarters

Pleasanton, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • Series F raised $40M led by Ally Bridge Group and Janus Henderson Investors.
  • CVAC system treated over 40,000 patients, advancing toward standard of care.
  • ASPIRE study at AUA showed superior clearance independent of stone burden in 101 patients.

What critics are saying

  • Boston Scientific's LithoClast Trilogy erodes market share via hospital contracts in 12-24 months.
  • Cook Medical's NGage basket undercuts CVAC pricing by 30% in 12-18 months.
  • FDA Class I recall triggers withdrawal due to 5% ureteral perforation risks in 3-9 months.

What makes Calyxo unique

  • CVAC System integrates ureteroscopy, laser lithotripsy, irrigation, and aspiration in one device.
  • SURE procedure with CVAC achieves 97% volumetric stone clearance versus standard URS.
  • Redesigned CVAC received FDA clearance in March 2024 for minimally invasive treatment.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Calyxo who can refer or advise you

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Stock Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

2%

2 year growth

8%
StreetInsider
Apr 14th, 2026
Calyxo raises $40M Series F as CVAC kidney stone system treats 40,000 patients

Calyxo, a medical device company focused on kidney stone treatment, has closed a $40 million Series F financing round led by Ally Bridge Group and Janus Henderson Investors. Questa Capital, Avidity Partners and CRG also participated. The funding follows a milestone of 40,000 patients treated with Calyxo's CVAC System, an aspiration-based stone removal device. The system uses irrigation and vacuum aspiration to continuously clear stone fragments during procedures, enabling more complete stone clearance. Proceeds will support commercial expansion, clinical evidence generation through ongoing studies evaluating long-term outcomes, and continued innovation in kidney stone care. The CVAC System received FDA clearance in 2024 and is positioned as an all-in-one solution for minimally invasive kidney stone removal.

Business Wire
May 14th, 2024
Study Presented At Aua Shows Superior Kidney Stone Clearance Rates For Sure Procedure Using Calyxo’S Cvac System Vs Standard Urs

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, has announced that positive study results for its CVAC System were presented last week at the American Urological Association (AUA) Annual Meeting in San Antonio. The CVAC System, a revolutionary technology that is designed for complete kidney stone removal, was the focus of the prospective, randomized, multi-center ASPIRE study, which compared the safety and efficacy of steerable ureteroscopic renal evacuation (SURE) vs ureteroscopy (URS) with basketing. The 30-day results of the ASPIRE study were presented at the AUA Meeting by urologist Thomas Chi, MD of the University of California, San Francisco. In 101 patients, SURE demonstrated statistically superior stone clearance and significantly lower residual stone volume compared to standard URS. Unlike standard URS, the CVAC System achieved these results independent of baseline stone burden. Safety was comparable between groups

Business Wire
Mar 26th, 2024
Calyxo Announces Fda Clearance For New, Redesigned Cvac System

PLEASANTON, Calif.--(BUSINESS WIRE)--Calyxo, Inc., a medical device company developing innovative solutions for patients with kidney stones, announced that it has received FDA clearance for its new, redesigned CVAC System, which enables a minimally invasive approach to kidney stone treatment. More than 50 procedures have already been completed by 12 urologists with the new CVAC System, yielding strong patient outcomes and consistently positive physician feedback. Clinical studies have shown that residual stone fragments are associated with a 20%-44% incidence of post-procedure problems, including pain, infection, emergency department visits, hospitalization and need for retreatment. Steerable ureteroscopic renal evacuation (SURE) using the original CVAC Aspiration System has been used to successfully treat more than 1,500 patients in the U.S., demonstrating that vacuum aspiration of stone fragments improves clinical outcomes, with 97% volumetric stone clearance and a high likelihood of avoiding the need for a secondary or more invasive procedure (according to clinical study data collected in patients treated with the device)

FinSMEs
Dec 12th, 2023
Calyxo Raises $50M in Series D Funding

Calyxo, a Pleasanton, CA-based medical device company developing next-generation treatment solutions for patients with kidney stones, raised $50M in Series D funding.

Questa Capital
Jul 6th, 2022
Questa Capital invests into Calyxoinc in $32.7M

Calyxo, Inc., a medical device company focused on improving care for patients with kidney stones by delivering next generation treatment solutions, has announced the closing of a $32.7 million Series C financing round led by Questa Capital and CRG.